BetterScholar BetterScholar
8
Role
Title
Level Year L/R
🐜 Same data, different conclusions: Radical dispersion in empirical results when independent analysts operationalize and test the same hypothesis
179 auth. Martin Schweinsberg, Michael Feldman, N. Staub, O. V. D. Akker, R. V. Aert, M. V. Assen, Yang Liu, Tim Althoff, Jeffrey Heer, Alex Kale, Zainab Mohamed, Hashem Amireh, Vaishali Venkatesh Prasad, A. Bernstein, E. Robinson, ... Kaisa Snellman, S. A. Sommer, Sarah M. G. Otner, David Robinson, Nikhil Madan, R. Silberzahn, P. Goldstein, W. Tierney, Toshio Murase, Benjamin Mandl, Domenico Viganola, C. Strobl, Catherine Schaumans, Stijn Kelchtermans, C. Naseeb, S. M. Garrison, T. Yarkoni, C. Chan, P. Adie, P. Alaburda, C. Albers, S. Alspaugh, J. Alstott, A. Nelson, Eduardo Ariño de la Rubia, Adbi Arzi, Š. Bahník, Jason Baik, Laura Winther Balling, S. Banker, D. Baranger, D. Barr, Brenda A. Barros-Rivera, M. Bauer, E. Blaise, Lisa Boelen, K. B. Carbonell, R. Briers, Oliver Burkhard, M. Canela, Laura Castrillo, Timothy S. Catlett, Olivia Chen, Michael Clark, Brent Cohn, A. Coppock, Natàlia Cugueró-Escofet, P. Curran, Wilson Cyrus-Lai, David Dai, G. D. Riva, H. Danielsson, R. Russo, N. Silva, C. Derungs, F. Dondelinger, Carolina Duarte de Souza, B. Dube, M. Dubova, B. Dunn, P. Edelsbrunner, Sara Finley, N. Fox, Timo Gnambs, Y. Gong, Erin Grand, Brandon Greenawalt, Dan Han, P. Hanel, Antony B. Hong, David Hood, Justin Hsueh, Lilian Huang, K. Hui, Keith A. Hultman, Azka Javaid, Lily Jiang, J. Jong, Jash Kamdar, David Kane, Gregor Kappler, E. Kaszubowski, C. Kavanagh, Madian Khabsa, Bennett Kleinberg, Jens Kouros, Heather Krause, Angelos-Miltiadis Krypotos, D. Lavbič, Ruiwen Lee, Timothy Leffel, Wei Yang Lim, S. Liverani, B. Loh, Dorte Lønsmann, Jia-Wei Low, Alton Lu, Kyle MacDonald, C. Madan, Lasse Hjorth Madsen, C. Maimone, A. Mangold, A. Marshall, He Matskewich, Kimia Mavon, Katherine L. McLain, Amelia A. McNamara, Mhairi McNeill, U. Mertens, David I Miller, Ben Moore, Andrew Moore, E. Nantz, Z. Nasrullah, Valentina Nejkovic, Colleen S. Nell, Andrew Nelson, G. Nilsonne, Rory Nolan, C. E. O'Brien, Patrick K. O'Neill, Kieran J O’Shea, Toto Olita, Jahna Otterbacher, Diana Palsetia, Bianca Pereira, I. Pozdniakov, John Protzko, J. Reyt, Travis A. Riddle, Amal Ridhwan Omar Ali, Ivan Ropovik, J. Rosenberg, S. Rothen, Michael Schulte-Mecklenbeck, Nirek Sharma, Gordon Shotwell, M. Skarzynski, Will Stedden, V. Stodden, M. Stoffel, Scott Stoltzman, Subashini Subbaiah, Rachael Tatman, P. Thibodeau, Sabina Tomkins, Ana Valdivia, Gerrieke B. Druijff-van de Woestijne, L. Viana, Florence Villesèche, W. D. Wadsworth, Florian Wanders, Krista L. Watts, J. D. Wells, Christopher E. Whelpley, Andy Won, Lawrence Wu, Arthur Yip, Casey Youngflesh, Ju‐Chi Yu, A. Zandian, Leilei Zhang, C. Zibman, E. Uhlmann
6 2021
6
🐜
🐜 Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
11 auth. J. Kremer, M. Genovese, E. Keystone, P. Taylor, S. Zuckerman, G. Ruotolo, ... D. Schlichting, Victoria L. Crotzer, E. Nantz, S. Beattie, W. Macias
5 2017
5
🐜
🐜 Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
15 auth. R. Hoffman, J. Merrill, M. Alarcón-Riquelme, M. Petri, E. Dow, E. Nantz, L. Nisenbaum, K. Schroeder, W. Komocsar, N. Perumal, ... M. Linnik, D. Airey, Yushi Liu, G. Rocha, R. Higgs
5 2016
5
🐜
🐜 Effect of Treatment With Tabalumab, a B Cell–Activating Factor Inhibitor, on Highly Sensitized Patients With End‐Stage Renal Disease Awaiting Transplantation
13 auth. M. Mujtaba, W. Komocsar, E. Nantz, M. Samaniego, S. Henson, J. A. Hague, A. Lobashevsky, N. Higgins, M. Czader, B. Book, ... M. Anderson, M. Pescovitz, T. Taber
5 2016
5
🐜
🦁 Predictors of premature discontinuation of treatment in multiple disease states
E. Nantz, H. Liu-Seifert, V. Skljarevski
4 2009
4
🦁
🐜 Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
12 auth. D. M. van der Heijde, P. Durez, G. Schett, E. Naredo, M. Østergaard, G. Mészáros, ... F. De Leonardis, I. de la Torre, P. López-Romero, D. Schlichting, E. Nantz, R. Fleischmann
4 2018
4
🐜
🐜 Gene Expression and Pharmacodynamic-Induced Changes in 1 , 760 SLE Patients from Two Phase III Trials of B Cell Activating Factor Blockade with Tabalumab
15 auth. R. Hoffman, J. Merrill, M. Alarcón-Riquelme, M. Petri, E. Dow, E. Nantz, L. Nisenbaum, K. Schroeder, W. Komocsar, N. Perumal, ... M. Linnik, D. Airey, Yushi Liu, G. Rocha, R. Higgs
4 2016
4
🐜
🐢 Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study (P3.397)
M. Silk, E. Nantz
2 2018
2
🐢